Innovative Methods for Quantitating Host Residual DNA in Biologic Drugs

“Every lab that does host residual DNA from biologics should use the direct method, it will reduce work time and increase accuracy.”

Musaddeq Hussain Ph.D., Principal Scientist of Bioprocess Development at Merck Research Laboratories joined us at Biotech Week Boston to discuss innovation in quantifying host cell DNA for biologics. In this interview, he delves into the new state of the art methods of quantifying host cell DNA for biologics, which of those methods are especially useful improvements, the types of products that require customization, where new/more sensitive technologies are needed, and the¬†existing solutions that companies don’t know they can take advantage of. To hear Dr. Hussain’s exclusive insights on these key industry trends,¬†access the complete interview now.

Continue reading “Innovative Methods for Quantitating Host Residual DNA in Biologic Drugs”

State of the Industry: Innovation and the Hype Cycle

Taken from Christopher V. Gemmiti’s speech at our last Cell Therapy Manufacturing & Gene Therapy Congress, he spoke at length on the state of the industry, and how far we have come since the early 90’s and where we now find ourselves. Here’s what Christopher had to say.

Continue reading “State of the Industry: Innovation and the Hype Cycle”